Is resective surgery cost-effective for adults with epilepsy? A cost-utility analysis in a publicly funded healthcare system

Bonnon, Alexandra, Kopanidis, Paul, Kemmis-Betty, Sophia, Wonderling, David, de Tisi, Jane, Miserocchi, Anna, Sleem, Osama, Zisakis, Ilijana Sumonja, Winterbottom, Janine, Ziso, Besa, Marson, Anthony G., Cooper, Paul, Mohanraj, Rajiv, Chauhan, Vanisha, Faulkner, Howard, Slaght, Sean J., Adcock, Jane, Kinton, Lucy, Akay, Ela Melisa, Ellawela, Shan, Mullatti, Nandini, Khalid, Hamandi, Sieradzan, Katarzyna, Chelvarajah, Ramesh, Cross, Judith Helen, Duncan, John Sidney and Sen, Arjune 2025. Is resective surgery cost-effective for adults with epilepsy? A cost-utility analysis in a publicly funded healthcare system. Journal of Neurology, Neurosurgery and Psychiatry 10.1136/jnnp-2025-336197

PDF - Accepted Post-Print Version Download (348kB)

Abstract

Background: Resective epilepsy surgery is an established clinical intervention, but the cost-effectiveness at a national healthcare level is uncertain. This study evaluates the cost-effectiveness of resective epilepsy surgery compared with medical management in adults from national healthcare and personal social services perspectives. Methods: A de novo decision analytic model was developed, comprising a 1-year decision tree and lifetime Markov model to evaluate lifetime costs and quality-adjusted life years (QALYs). Data were obtained from UK epilepsy surgery centres to evaluate the costs of preoperative assessment and the probability of undergoing resection after presurgical evaluation. Other clinical inputs were obtained from a systematic literature review. The main outcome of the analysis was the incremental cost-effectiveness ratio (ICER), with a cost-effectiveness threshold set at £20 000 cost per QALY gained. Results: Data from 762 patients informed preoperative evaluation costs and the probability of undergoing epilepsy surgery after presurgical evaluation. The total lifetime cost of epilepsy treatment for people who had surgical treatment was £56 911, compared with £32 490 for medical management. Total QALYs per person for surgery were 15.91 and 13.76 for medical management. Resective epilepsy surgery was shown to be cost-effective with an ICER of £11 348 per QALY gained. Conclusions: Our data inform and strengthen recommendations to prioritise referral of those with drug-refractory epilepsy to surgical centres. We provide a health economic rationale for the development and support of resective epilepsy surgery programmes across national healthcare systems.

Item Type:	Article
Date Type:	Published Online
Status:	In Press
Schools:	Schools > Psychology Research Institutes & Centres > Cardiff University Brain Research Imaging Centre (CUBRIC)
Publisher:	BMJ Publishing Group
ISSN:	0022-3050
Date of First Compliant Deposit:	28 October 2025
Date of Acceptance:	17 July 2025
Last Modified:	28 Oct 2025 12:00
URI:	https://orca.cardiff.ac.uk/id/eprint/181945

Actions (repository staff only)

Edit Item